Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

181. Proton pump inhibitor treatment for acute peptic ulcer bleeding. (Full text)

Proton pump inhibitor treatment for acute peptic ulcer bleeding. Randomised controlled trials (RCTs) evaluating the clinical effect of proton pump inhibitors (PPIs) in peptic ulcer (PU) bleeding yield conflicting results.To evaluate the efficacy of PPIs in acute bleeding from PU using evidence from RCTs.We searched CENTRAL, The Cochrane Library (Issue 4, 2004), MEDLINE (1966 to November 2004), EMBASE (1980 to November 2004), proceedings of major meetings to November 2004, and reference lists

2006 Cochrane PubMed

182. A systematic review of the role of proton pump inhibitors for symptoms of laryngopharyngeal reflux

A systematic review of the role of proton pump inhibitors for symptoms of laryngopharyngeal reflux A systematic review of the role of proton pump inhibitors for symptoms of laryngopharyngeal reflux A systematic review of the role of proton pump inhibitors for symptoms of laryngopharyngeal reflux Sen P, Georgalas C, Bhattacharyya A K CRD summary This review assessed the efficacy of proton-pump inhibitors in the treatment of laryngopharyngeal reflux in adults. The authors concluded (...) that there was insufficient evidence on which to base conclusions regarding the effectiveness of the intervention, and further randomised trials are required. Despite limitations to this review, the authors' cautious conclusions are justified give the data available. Authors' objectives To assess the efficacy of proton-pump inhibitors (PPIs) in the treatment of laryngopharyngeal reflux in adults. Searching MEDLINE (from 1966), EMBASE (from 1980) and the Cochrane Controlled Trials Register were searched up to October 2004

2006 DARE.

183. Empiric treatment of laryngopharyngeal reflux with proton pump inhibitors: a systematic review

Empiric treatment of laryngopharyngeal reflux with proton pump inhibitors: a systematic review Empiric treatment of laryngopharyngeal reflux with proton pump inhibitors: a systematic review Empiric treatment of laryngopharyngeal reflux with proton pump inhibitors: a systematic review Karkos P D, Wilson J A CRD summary This review evaluated the use of proton-pump inhibitors (PPIs) for the treatment of laryngopharyngeal reflux and found no evidence to demonstrate superiority of PPIs over placebo (...) . Limitations in the reporting of the included studies and review methodology mean that it is not possible to comment on the robustness of the evidence presented or the authors' conclusion. Authors' objectives To evaluate the treatment of suspected laryngopharyngeal reflux (LPR) symptoms with proton-pump inhibitors (PPIs). Searching MEDLINE, EMBASE, CINAHL and the Cochrane Library were searched for studies published in any language; the search terms were reported. References from relevant articles were also

2006 DARE.

184. A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori

A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

185. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis. A comparison of esomeprazole with other PPIs

Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis. A comparison of esomeprazole with other PPIs Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

186. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials

Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

187. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials

Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

188. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. (Full text)

Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. To review randomised controlled trials of treatment with a proton pump inhibitor in patients with ulcer bleeding and determine the impact on mortality, rebleeding, and surgical intervention.Systematic review and meta-analysis.Cochrane Collaboration's trials register, Medline, and Embase, handsearched abstracts, and pharmaceutical companies.Included randomised controlled trials compared proton pump (...) inhibitor with placebo or H2 receptor antagonist in endoscopically proved bleeding ulcer and reported at least one of mortality, rebleeding, or surgical intervention. Trials were graded for methodological quality. Two assessors independently reviewed each trial, and disagreements were resolved by consensus.We included 21 randomised controlled trials comprising 2915 patients. Proton pump inhibitor treatment had no significant effect on mortality (odds ratio 1.11, 95% confidence interval 0.79 to 1.57

2005 BMJ PubMed

189. Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK

Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK Remak E, Brown R E, Yuen C, Robinson A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of proton-pump inhibitors (PPIs) to treat gastro-oesophageal reflux disease (GORD). Seven PPIs were compared. These were esomeprazole, lansoprazole capsules, lansoprazole oro-dispersible tablets, omeprazole (generic and branded), pantoprazole and rabeprazole. Type of intervention

2005 NHS Economic Evaluation Database.

190. Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease

Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease Hughes D, Bodger K, Bytzer P, De Herdt D, Dubois D Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined several on-demand maintenance therapies with oral proton-pump inhibitors (PPIs) in patients with endoscopy-confirmed non-erosive reflux disease (NERD). The PPIs studied were esomeprazole 20 mg, lansoprazole 15 mg, omeprazole 10 and 20 mg

2005 NHS Economic Evaluation Database.

191. 'Proton-pump inhibitor-first' strategy versus 'step-up' strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan

'Proton-pump inhibitor-first' strategy versus 'step-up' strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan 'Proton-pump inhibitor-first' strategy versus 'step-up' strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan 'Proton-pump inhibitor-first' strategy versus 'step-up' strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan Habu Y, Maeda K, Kusuda T, Yoshino T, Shio S (...) on a first-line proton-pump inhibitor (PPI), lansoprazole 30 mg/day (LAN), for 8 weeks (plus a further 12 weeks for unhealed patients). The other was a step-up approach in which patients started with a histamine H2-receptor antagonist (H2RA), ranitidine 300 mg/day (RAN), for 8 weeks and then switched to LAN in case of failure. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of patients

2005 NHS Economic Evaluation Database.

192. Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials

Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials Mcquaid K R, Laine L CRD summary This review assessed proton-pump inhibitors for the relief of heartburn within 1 to 2 days. The authors concluded that proton pump (...) inhibitors may improve symptoms within 24 hours, but most patients will not experience relief in the first 1 or 2 days. Apart from the limited search, this was a well-conducted review and the authors' conclusions are likely to be reliable. Authors' objectives To assess the efficacy of proton-pump inhibitors (PPIs) for heartburn relief within the first 1 to 2 days of treatment. Searching MEDLINE (1966 to June 2004) and EMBASE (1980 to June 2004) were searched without language restrictions; the search

2005 DARE.

193. Short-term cost effectiveness and long-term cost analysis comparing laparoscopic Nissen fundoplication with proton-pump inhibitor maintenance for gastro-oesophageal reflux disease

Short-term cost effectiveness and long-term cost analysis comparing laparoscopic Nissen fundoplication with proton-pump inhibitor maintenance for gastro-oesophageal reflux disease Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 NHS Economic Evaluation Database.

194. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer?

Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

195. Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses

Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

196. Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain: a meta-analysis

Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

197. Meta-analysis: the influence of pre-treatment with a proton pump inhibitor on Helicobacter pylori eradication

Meta-analysis: the influence of pre-treatment with a proton pump inhibitor on Helicobacter pylori eradication Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

198. Effectiveness of proton pump inhibitors in nonerosive reflux disease

Effectiveness of proton pump inhibitors in nonerosive reflux disease Effectiveness of proton pump inhibitors in nonerosive reflux disease Effectiveness of proton pump inhibitors in nonerosive reflux disease Dean B B, Gano A D, Knight K, Ofman J J, Fass R CRD summary This review assessed the use of proton-pump inhibitors (PPIs) to relieve the symptoms of nonerosive reflux disease (NERD). The authors concluded that PPIs have a lesser effect in NERD than in erosive oesophagitis, and that symptoms (...) tended to improve throughout the 4-week period. Insufficient data were presented to assess the appropriateness of pooling the studies, hence any conclusions may not be reliable. Authors' objectives To assess the effectiveness of proton-pump inhibitors (PPIs) for the relief of symptoms of nonerosive reflux disease (NERD), and also to assess the effects of PPIs in patients with NERD compared with patients with erosive oesophagitis (EE). Searching MEDLINE and HealthSTAR were searched for studies

2004 DARE.

199. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics

Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics Numans M E, Lau J, de Wit N J, Bonis P A CRD summary (...) This review assessed the accuracy of symptomatic response to proton-pump inhibitor (PPI) treatment in the diagnosis of gastroesophageal reflux disease (GERD). The authors concluded that a response to short-term treatment with PPIs does not accurately diagnose GERD as defined by traditional objective criteria. The authors' conclusions are likely to be reliable. Authors' objectives To determine the diagnostic accuracy of symptomatic response to proton-pump inhibitor (PPI) treatment as an indicator

2004 DARE.

200. Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding

Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding Erstad B L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study evaluated the use of adjunctive oral and intravenous proton-pump inhibitor (PPI) therapies for patients with acute peptic ulcer-related bleeding of sufficient severity to warrant hospitalisation. Four clinical scenarios were considered. Scenario 1 was diagnostic endoscopy and oral PPI therapy (40 mg twice daily of omeprazole or the equivalent dose of another PPI for 5 days). Scenario 2

2004 NHS Economic Evaluation Database.